How to Screen for Undervalued Biotech Stocks

Screening in a Sector With No Earnings

Screening for value in biotech is harder than in most sectors because the usual metrics — P/E, free cash flow — don't apply to pre-revenue companies. Value in clinical-stage biotech comes from the gap between a pipeline's risk-adjusted worth and the market's price, filtered through the company's ability to survive long enough to realize it. A good screen combines several dimensions rather than chasing one number.

The Dimensions That Matter

A robust biotech screen weighs:

1. Cash and runway. Cash runway — cash divided by burn rate — is the survival metric. A company with a runway that comfortably clears its next catalyst is in control; one that doesn't faces forced dilution. Compare cash to market cap: a company trading near its net cash may be pricing in little pipeline value, which can be an opportunity or a warning.
2. Catalysts. Near-term catalysts — a Phase 3 readout, a PDUFA date — are what re-rate a stock. A cheap company with no catalysts can stay cheap for years; a cheap company with a high-quality catalyst within the runway is far more interesting.
3. Pipeline quality. How many programs, at what phase, targeting what indications, with what mechanism of action? Depth provides shots on goal; a single-asset company is a concentrated bet.
4. Valuation. Compare the market cap (net of cash) to a rough rNPV of the pipeline. The screen is hunting for cases where the implied assumptions look too pessimistic.

The art is combining these — a cheap company with a strong near-term catalyst, an adequate runway, and a credible pipeline is a very different prospect from a cheap company missing any one of those.

From Filters to a Watchlist

A practical workflow:

• Start broad with hard filters: minimum runway (say, enough to reach the next catalyst), a catalyst within a defined window, a minimum pipeline depth.
• Rank by valuation gap — where price looks low relative to risk-adjusted pipeline value.
• Then go deep on the survivors with real due diligence: trial design, endpoint quality, competitive landscape, and management track record. A screen finds candidates; it doesn't replace analysis.

The Data Problem — and Natural-Language Screening

The traditional obstacle is that these dimensions live in different places: cash and burn in SEC filings, trials on ClinicalTrials.gov, catalysts scattered across disclosures, FDA actions elsewhere. Manually assembling a screen across all of them, for hundreds of companies, is slow and error-prone.

This is where natural-language screening changes the workflow. Instead of building complex filters by hand, you describe what you want in plain language — for example, "clinical-stage oncology companies with a Phase 3 readout in the next 90 days and over 18 months of cash runway." The system compiles that into structured queries across every data field — financials, trials, catalysts, indications — and returns the matching companies. Any field becomes a screening criterion, and the cross-source assembly that used to take hours happens in seconds.

Avoiding the Value Trap

The biggest risk in value screening is the value trap — a stock that's cheap for a reason. In biotech, traps include:

• A short runway guaranteeing dilution before the catalyst.
• A failed or deprioritized lead program the market has already discounted.
• A crowded mechanism where the company is hopelessly behind.

This is why catalysts and runway belong in the screen alongside valuation: cheapness without a path to re-rating, and without the cash to get there, is usually a trap.

Applying It

Build your screen around the combination — runway, catalysts, pipeline quality, and valuation — not any single metric. Use natural-language screening to assemble candidates quickly across all the data, then do deep due diligence on the finalists. Track the catalysts that could re-rate them on the catalyst calendar, and estimate survival with the cash runway tool.

In biotech, "undervalued" means the market is too pessimistic about a pipeline the company can actually afford to advance to its next catalyst — and a disciplined, multi-factor screen is how you find those cases.